Time to complete:
Date of publication:
This is a recording of a live webinar that took place on 12 May 2021. This recording will be available to view until 26 Feburary 2022.
Join us for this FREE live 90-minute webinar focusing on the basics of Type 2 Diabetes and how this disease interacts with the cardiorenal-metabolic systems.
People with type 2 diabetes are at greatly increased risk not just of cardiovascular events but of microvascular complications, including nephropathy.
The presence of diabetic nephropathy is associated with worse outcomes in type 2 diabetes – 10 year mortality is increased by 18% in the presence of albuminuria, 24% if eGFR is below 60 and 47% if both are present compared to a person with type 2 diabetes and neither complication1.
While tight glycaemic control can improve microvascular outcomes, recent years have seen the development of medications which slow development of nephropathy in people with type 2 diabetes.
1. Afkarian M et al. J Am Soc Nephrol 2013;24:302
- Understand the epidemiology of type 2 diabetes and of cardiorenal-metabolic complications.
- Appreciate the implications of renal complications within the cardiorenal-metabolic system.
- Examine the relative impact of glycaemic control and medications targeting the cardiorenal-metabolic system on outcomes for people with type 2 diabetes.
Dr Sarah Jarvis MBE, GP and Clinical Director of Patient.info.
Professor Richard Hobbs, Nuffield Professor of Primary Care at the University of Oxford, and Head of the Nuffield Department of Primary Care Health Sciences
Dr Andrew Frankel, Consultant Renal Physician, Imperial College London
Dr Jim Moore, President of the Primary Care Cardiovascular Society
This webinar is funded by:
This series of medical education webinars is sponsored by Boehringer Ingelheim and Lilly Diabetes Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of faculty. Editorial and content decisions were made solely by the RCGP and faculty chosen by RCGP.